News
We send the latest information from SMC Laboratories.
NeuroVive Pharmaceutical’s publication on Cells.
SMC announced that NeuroVive Pharmaceutical has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis”
Dokkyo Medical University’s publication on International Journal of Molecular Sciences.
SMC announced that Dokkyo Medical University has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”
FDA-National Center for Toxicological Research’s publication on Toxicological Sciences.
SMC announced that FDA-National Center for Toxicological Research has published the results of a study using STAM™ model on Toxicological Sciences. Title: “Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis”
University of Nebraska’s publication on Biochemistry.
SMC announced that University of Nebraska has published the results of a study using STAM™ model on Biochemistry. Title: “A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease”
Genomics Institute of the Novartis Research Foundation’s publication on Hepatology Communications.
SMC announced that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model on Hepatology Communications. Title: “Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with the Antioxidative Gene Expression Profile in Rodents”
FDA-National Center for Toxicological Research’s publication in Frontiers in Genetics.
SMC announced that FDA-National Center for Toxicological Research (NCTR) published the results of a study using STAM™ model in Frontiers in Genetics. Title: Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis Read more…https://www.ncbi.nlm.nih.gov/pubmed/31191608
Enanta Pharmaceuticals, Inc’s publication on the International Journal of Gastroenterology.
SMC announces that Enanta Pharmaceuticals, Inc. has published the results of a study using the STAM™ model in the International Journal of Gastroenterology. Title: Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis Read more…. http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=282&doi=10.11648/j.ijg.20190301.12
Kanagawa University of Human Services’ publication on Experimental Animals.
SMC announced that Kanagawa University of Human Services has published the results of a study using STAM™ model on Experimental Animals. Title: “Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice” Read more…. https://www.ncbi.nlm.nih.gov/pubmed/31155606
Osaka Medical College’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that Osaka Medical College presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Influence of the O-GlcNAc Modification in Hepatic Carcinogenesis by Non-alcoholic Fatty Liver Disease”
TSUMURA & Co.’s presentation at DDW® 2019 in San Diego, CA.
SMC announced that TSUMURA & Co. presented results of a study using STAM™ model at poster presentation at DDW® 2019 in San Diego, CA, May 18-21, 2019. Title: “Change of Gut Microbiome after Treatment with the Traditional Japanese Medicine Daisaikoto is Associated with Improved Liver Steatosis in a Non-alcoholic Fatty Liver Mouse Model”